Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension

NCT06052748 is registered in ClinicalTrials.gov with Addpharma Inc. as lead sponsor.

NCT NCT06052748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension
Lead sponsor
Addpharma Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 15, 2024
Completion date
April 2, 2025
Enrollment
502 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension,essential